{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:10:42Z","timestamp":1760865042737},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1996,6,1]],"date-time":"1996-06-01T00:00:00Z","timestamp":833587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"published-print":{"date-parts":[[1996,6]]},"DOI":"10.1007\/bf00148169","type":"journal-article","created":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:10:46Z","timestamp":1099267846000},"page":"155-165","source":"Crossref","is-referenced-by-count":23,"title":["The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine"],"prefix":"10.1007","volume":"12","author":[{"given":"C. R.","family":"Valentine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Leakey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Casciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archneur.1986.00520110011006","volume":"43","author":"OA Agbato","year":"1986","unstructured":"Agbato OA,Abdulmajid AE, Patsalos PN, Brett EM, Lascellas PT. Total and free serum concentration of carbamazepine and carbamazepine-10, 11-episode in children with epilepsy. arch Neurol. 1986;43:1111?6.","journal-title":"arch Neurol."},{"key":"CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/clpt.1980.13","volume":"27","author":"L Bertilsson","year":"1980","unstructured":"Bertilsson L, H\ufffdjer B, Tybring G, Osterloh J, Rane A. Auto-induction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther. 1980;27:83?8.","journal-title":"Clin Pharmacol Ther."},{"key":"CR3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archneur.1963.00460090091009","volume":"9","author":"S Blom","year":"1963","unstructured":"Blom S. Tic douloreux treated with new anticonvulsant: experience with G 32883. arch Neurol. 1963;9:285?90.","journal-title":"arch Neurol."},{"key":"CR4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0027-5107(84)90110-6","volume":"128","author":"CL Crespi","year":"1984","unstructured":"Crespi CL, Thilly WG. Assay for gene mutation in a human lymphoblast line, AHH-1, competent for xenobiotic metabolism. Mutat Res. 1984;128:221?30.","journal-title":"Mutat Res."},{"key":"CR5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0009-2797(85)80103-4","volume":"53","author":"CL Crespi","year":"1985","unstructured":"Crespi CL, Altman JD, Marletta MA. Xenobiotic metabolism in a human lymphoblastoid cell line. Chem Biol Interact. 1985;53:257?72.","journal-title":"Chem Biol Interact."},{"key":"CR6","first-page":"97","volume-title":"Progress in clinical and biological research","author":"CL Crespi","year":"1990","unstructured":"Crespi CL, Langenbach R, Penman BW. The development fo a panel of human cell lines expressing specific human cytochrome P450 cDNAs. In: Mendelsohn ML, Albertini RJ, eds. Progress in clinical and biological research. New York: Wiley-Liss; 1990;340B:97?106."},{"key":"CR7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/carcin\/12.2.355","volume":"12","author":"CL Crespi","year":"1991","unstructured":"Crespi CL, Penman BW, Steimel DT, Gelboin HV, Gonzalwz FJ. The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis. 1991a;12:355?9.","journal-title":"Carcinogenesis"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/tx00023a013","volume":"4","author":"CL Crespi","year":"1991","unstructured":"Crespi CL, Gonzalez FJ, Steimel Dt et al. Metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing. Chem Res Toxicol. 1991b;4:566?72.","journal-title":"Chem Res Toxicol."},{"key":"CR9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0300-483X(93)90062-W","volume":"82","author":"CL Crespi","year":"1993","unstructured":"Crespi CL, Langenbach R, Penman BW. Human cell lines, derived from AHH-1 TK+?human lymphobalsts, genetically engineered for expression of cytochromes P450. Toxicology. 1993a;82:89?104.","journal-title":"Toxicology"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1042\/bst0211023","volume":"21","author":"CL Crespi","year":"1993","unstructured":"Crespi CL, Penman BW, Gonzalez FJ, Gelboin HV, Galvin M, Langenbach R. Genetic toxicology using human cell lines expressing human P-450. Biochem Soc Trans. 1993b;211023?8.","journal-title":"Biochem Soc Trans."},{"key":"CR11","first-page":"491","volume-title":"Antiepileptic drugs","author":"JW Faigle","year":"1989","unstructured":"Faigle JW, Feldmann KF.Carbamazepine biotransformation. In: Levy R, Meldrum B, Penry B, Penry JK, Dreifuss FE, eds. Antiepileptic drugs. New York: Raven Press; 1989:491?504."},{"key":"CR12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0165-6147(92)90107-H","volume":"13","author":"FJ Gonzalez","year":"1992","unstructured":"Gonzalez FJ. Human cytochrome P450: problems and prospects. Trends Pharmacol Sci. 1992;13:346?52.","journal-title":"Trends Pharmacol Sci."},{"key":"CR13","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S, A simple sequently rejective multiple test procedure. Sacn J Statist. 1979;6:65?70.","journal-title":"Sacn J Statist."},{"key":"CR14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cpt1975174433","volume":"17","author":"WD Hooper","year":"1975","unstructured":"Hooper WD, Dubetz DK, Bochner F et al. Plasma protein binding of carbamazepine. Clin Pharmacol Ther. 1975;17:433?40.","journal-title":"Clin Pharmacol Ther."},{"key":"CR15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0887-2333(93)90125-O","volume":"7","author":"T Husoy","year":"1993","unstructured":"Husoy T, syversen T, Jenssen J. Comparison of fourin vitro cytotoxicity tests: the MTT assay, NR assay, uridine incorporation and protein measurements. Toxicol In Vitro. 1993;7:149?54.","journal-title":"Toxicol In Vitro."},{"key":"CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0887-2333(92)90084-5","volume":"6","author":"R Jover","year":"1992","unstructured":"Jover R, Ponsoda X, Castell JV, G\ufffdmez-Lech\ufffdn MJ. Evaluation of the cytotoxicity of ten chemicals on human cultured hepatocytes: predictability of human toxicity and comparison with rodent cell culture systems. Toxicol In Vitro. 1992;6:47?52.","journal-title":"Toxicol In Vitro"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","volume":"47","author":"BM Kerr","year":"1994","unstructured":"Kerr BM, Thummel KE, Wurden CJ et al. Human liver carbamazepine metabolism ? role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47:1969?79.","journal-title":"Biochem Pharmacol."},{"key":"CR18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-2008-1073024","volume":"25","author":"R Korinthenberg","year":"1994","unstructured":"Korinthenberg R, Haug C, Hannak D. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence. Neuropediatrics. 1994;25:214?6.","journal-title":"Neuropediatrics"},{"key":"CR19","first-page":"1","volume":"10","author":"K Lertratanangkoon","year":"1982","unstructured":"Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Dispos. 1982;10:1?10.","journal-title":"Drug Metab Dispos."},{"key":"CR20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","volume":"13","author":"RH Mattson","year":"1985","unstructured":"Mattson RH, Cramer JA, Collins JF et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;13:145?51.","journal-title":"N Engl J Med."},{"key":"CR21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55?63.","journal-title":"J Immunol Methods"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1111\/j.1528-1157.1987.tb05780.x","volume":"28(suppl)","author":"JM Pellock","year":"1987","unstructured":"Pellock JM. Carbamazepine side effects in children and adults. Epilepsia. 1987;28(suppl):S64?70.","journal-title":"Epilepsia"},{"key":"CR23","volume-title":"Epilepsy: diagnosis, management and quality of life","author":"JK Penry","year":"1986","unstructured":"Penry JK. Epilepsy: diagnosis, management and quality of life. New York: Raven Press; 1986."},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/0006-2952(92)90696-G","volume":"43","author":"M Pirmohamed","year":"1992","unstructured":"Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepinein vitro. Biochem Pharmacol. 1992;43:1675?82.","journal-title":"Biochem Pharmacol."},{"key":"CR25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cpt1976193276","volume":"19","author":"A Rane","year":"1976","unstructured":"Rane A, H\ufffdjer B, Wilson JT. Kineticscs of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther. 1976;19:276?83.","journal-title":"Clin Pharmacol Ther."},{"key":"CR26","first-page":"345","volume":"11","author":"EH Reynolds","year":"1975","unstructured":"Reynolds EH. Neurotoxicity of carbamazepine. Adv Neurol. 1975;11:345?53.","journal-title":"Adv Neurol."},{"key":"CR27","first-page":"501","volume":"5","author":"K Schirrmacher","year":"1995","unstructured":"Schirrmacher K, Mayer A, Walden J, Dusing R, Bingmann D. Effects of carbamazepine on membrane properties of rat sensory spinal ganglion cells in vitro. Neuropsychobiology. 1995;5:501?7.","journal-title":"Neuropsychobiology"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00936891","volume":"242","author":"S Schmidt","year":"1995","unstructured":"Schmidt S, Schmitzbuhl M. Signs and symptoms of carbamazepine overdose. J Neurol. 1995;242:169?73.","journal-title":"J Neurol."},{"key":"CR29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1469-8749.1984.tb08169.x","volume":"26","author":"JF Schoeman","year":"1984","unstructured":"Schoeman JF, Elyas AA, Brett EM, Lascelles PT. Correlation between plasma carbamazepine-10, 11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol. 1984;26:756?64.","journal-title":"Dev Med Child Neurol."},{"key":"CR30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jama.1994.03510340057034","volume":"271","author":"D Scolnik","year":"1994","unstructured":"Scolnik D, Nulman I, Rovet J et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. J Med Assoc. 1994;271:767?70.","journal-title":"J Med Assoc."},{"key":"CR31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007691-199412000-00001","volume":"16","author":"F Semah","year":"1994","unstructured":"Semah F, Gimenez F, Longer E, Laplane D, Thuillier A, Baulac M. Carbamazepine and its epoxide ? an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy. Ther Drug Monitoring. 1994;16:537?40.","journal-title":"Ther Drug Monitoring"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1095\/biolreprod45.6.876","volume":"45","author":"JE Seng","year":"1991","unstructured":"Seng JE, Leakey JE, Arlotto MP, Parkinson A, Gandy J. Cellular localization of cytochrome P450IIA1 in testes of mature Sprague-Dawley rats. Biol Reprod. 1991;45:876?82.","journal-title":"Biol Reprod."},{"key":"CR33","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI113798","volume":"82","author":"NH Shear","year":"1988","unstructured":"Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest. 1988;82:1826?32.","journal-title":"J Clin Invest."},{"key":"CR34","first-page":"1214","volume":"24","author":"JL Sobotka","year":"1990","unstructured":"Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP Ann Pharmacother. 1990;24:1214?9.","journal-title":"DICP Ann Pharmacother."},{"key":"CR35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archneur.1984.04210080006004","volume":"41","author":"T Tomson","year":"1984","unstructured":"Tomson T, Bertilsson L. Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol. 1984;41:598?601.","journal-title":"Arch Neurol."},{"key":"CR36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archneur.1990.00530080072013","volume":"47","author":"T Tomson","year":"1990","unstructured":"Tomson T, Almkvist O, Nilsson BY, Svensson J-O, Bertilsson L. Carbamazepine-10, 11-epoxide in epilepsy ? a pilot study. Arch Neurol. 1990;47:888?92.","journal-title":"Arch Neurol."},{"key":"CR37","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/carcin\/13.12.2197","volume":"13","author":"INH White","year":"1992","unstructured":"White INH, Dematteis F, Davies A et al. Genotoxic potential of tamoxifen and analogues in female Fischer F3444\/N rats, DBA\/2 and C57BL\/6 mice and in human MCL-5 cells, Carcinogenesis. 1992;13:2197?203.","journal-title":"Carcinogenesis"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0006-8993(95)01066-1","volume":"703","author":"G Xiao-Ming","year":"1995","unstructured":"Xiao-Ming G, Margolis RL, Leeds P, Hough C, Post RM, Chuang D-M. Carbamazepine induction of apoptosis in cultured cerebellar neurons: effects ofN-methyl-d-aspartate, aurintricarboxylic acid and cycloheximide. Brain Res. 1995;703:63?71.","journal-title":"Brain Res."}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00148169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00148169\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00148169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:01:09Z","timestamp":1554274869000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00148169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,6]]}},"alternative-id":["BF00148169"],"URL":"https:\/\/doi.org\/10.1007\/bf00148169","relation":{},"ISSN":["0742-2091","1573-6822"],"issn-type":[{"value":"0742-2091","type":"print"},{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,6]]}}}